<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">80625</article-id><article-id pub-id-type="doi">10.7554/eLife.80625</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Short Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>Discovery and biological evaluation of a potent small molecule CRM1 inhibitor for its selective ablation of extranodal NK/T cell lymphoma</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-285144"><name><surname>Liu</surname><given-names>He</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-285145"><name><surname>Liu</surname><given-names>Meisuo</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-285146"><name><surname>Tian</surname><given-names>Xibao</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-285147"><name><surname>Wang</surname><given-names>Haina</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-300050"><name><surname>Gao</surname><given-names>Jiujiao</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-285148"><name><surname>Li</surname><given-names>Hanrui</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-285149"><name><surname>Zhao</surname><given-names>Zhehuan</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-285150"><name><surname>Liu</surname><given-names>Yu</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-156274"><name><surname>Liu</surname><given-names>Caigang</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2083-235X</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-285151"><name><surname>Chen</surname><given-names>Xuan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-217314"><name><surname>Yang</surname><given-names>Yongliang</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0449-0599</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">School of Bioengineering</institution>, <institution>Dalian University of Technology</institution>, <addr-line><named-content content-type="city">Dalian</named-content></addr-line>, <country>China</country></aff><aff id="aff2"><institution content-type="dept">School of Software</institution>, <institution>Dalian University of Technology</institution>, <addr-line><named-content content-type="city">Dalian</named-content></addr-line>, <country>China</country></aff><aff id="aff3"><institution content-type="dept">Department of Oncology</institution>, <institution>Shengjing Hospital of China Medical University</institution>, <addr-line><named-content content-type="city">Shenyang</named-content></addr-line>, <country>China</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-159305"><name><surname>Zhang</surname><given-names>Qing</given-names></name><role>Reviewing editor</role><aff><institution>University of Texas Southwestern Medical Center</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>angel-s205@163.com</email> (CL);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>everbright99@foxmail.com</email> (YY);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>27</day><month>10</month><year>2023</year></pub-date><volume>12</volume><elocation-id>e80625</elocation-id><history><date date-type="received"><day>27</day><month>05</month><year>2022</year></date><date date-type="accepted"><day>24</day><month>10</month><year>2023</year></date></history><permissions><copyright-statement>© 2023, Liu et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Liu et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-80625-v1.pdf"/><abstract><p><bold>Background:</bold> The overactivation of NF-κB signaling is a key hallmark for the pathogenesis of extranodal natural killer/T cell lymphoma (ENKTL), a very aggressive subtype of non-Hodgkin's lymphoma yet with rather limited control strategies. Previously, we found that the dysregulated exportin-1 (also known as CRM1) is mainly responsible for tumor cells to evade apoptosis and promote tumor-associated pathways such as NF-κB signaling.</p><p><bold>Methods:</bold> Herein we reported the discovery and biological evaluation of a potent small molecule CRM1 inhibitor, LFS-1107. We validated that CRM1 is a major cellular target of LFS-1107 by biolayer interferometry assay (BLI) and the knockdown of CRM1 conferred tumor cells with resistance to LFS-1107.</p><p><bold>Results:</bold> We found that LFS-1107 can strongly suppresses the growth of ENKTL cells at low-range nanomolar concentration yet with minimal effects on human platelets and healthy peripheral blood mononuclear cells. Treatment of ENKTL cells with LFS-1107 resulted in the nuclear retention of IkB<sub>a</sub> and consequent strong suppression of NF-kB transcriptional activities, NF-kB target genes downregulation and attenuated tumor cell growth and proliferation. Furthermore, LFS-1107 exhibited potent activities when administered to immunodeficient mice engrafted with human ENKTL cells.</p><p><bold>Conclusions:</bold> Therefore, LFS-1107 holds great promise for the treatment of ENKTL and may warrant translation for use in clinical trials.</p><p><bold>Funding:</bold> Yang's laboratory was supported by the National Natural Science Foundation of China (Grant: 81874301), the Fundamental Research Funds for Central University (Grant: DUT22YG122) and the Key Research project of 'be Recruited and be in Command' in Liaoning Province (Personal Target Discovery for Metabolic Diseases).</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>81874301</award-id><principal-award-recipient><name><surname>Liu</surname><given-names>He</given-names></name><name><surname>Liu</surname><given-names>Meisuo</given-names></name><name><surname>Tian</surname><given-names>Xibao</given-names></name><name><surname>Wang</surname><given-names>Haina</given-names></name><name><surname>Gao</surname><given-names>Jiujiao</given-names></name><name><surname>Li</surname><given-names>Hanrui</given-names></name><name><surname>Zhao</surname><given-names>Zhehuan</given-names></name><name><surname>Liu</surname><given-names>Yu</given-names></name><name><surname>Chen</surname><given-names>Xuan</given-names></name><name><surname>Yang</surname><given-names>Yongliang</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>U20A20381,82373063</award-id><principal-award-recipient><name><surname>Liu</surname><given-names>Caigang</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Caigang Liu, Senior editor, <italic>eLife</italic>.</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: Animal studies in the present work have been conducted in accordance with the ethical standards and the Declaration of Helsinki. The investigation has been approved by the Research Ethics Committee (REC) of Dalian University of Technology (approval number: 2018-023).</p></fn><fn fn-type="other"><p>Human subjects: The Research Ethics Committee (REC) of Dalian University of Technology approved conduct of ex vivo assays with donated human cells (approval number: 2018-023). Normal human peripheral blood mononuclear cells (PBMCs) were obtained from blood samples collected from healthy volunteers. Approval was obtained from The Second Affiliated Hospital of Dalian Medical University institutional review board for these studies.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data generated or analyzed during this study are included in the manuscript and supporting file. Source data files have been provided for Figures 1, 2 and 3 as well as their associated Supplemental Figures.</p></sec><supplementary-material><ext-link xlink:href="elife-80625-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>